Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Ipca Laboratories Ltd. Capital/Financing Update 2020

Sep 2, 2020

61700_rns_2020-09-02_97c5d64e-c91d-4d87-a053-aff1c6e7773a.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

THRU ONLINE FILING

September 2, 2020

BSE Limited Phiroze Jeejeebhoy Towers 27[th] Floor, Dalal Street Mumbai 400 023

The National Stock Exchange of India Ltd. Exchange Plaza, 5[th] Fir, Plot # C/1 G Block, Bandra-Kurla Complex, Bandra (E), Mumbai 400 051.

Sub: Re-affirmation of CRISIL rating for Company's Rs. 50 crores commercial paper programme

This is to inform you that CRISIL has re-affirmed its rating for the Company's commercial paper programme:

IRS. 50 crores Commercial Paper I CRISIL A 1+ (Reaffirmed)

This is for your information and record.

This is for your information.

Thanking you

Yours faithfully For Ipca Laboratories Limited V~ - ~-

Harish P. Kamath Corporate Counsel & Company Secretary

Ipea Laboratories Ltd. www.ipea.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India I T: +91 2262105000 F:+91 22 62105005 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India I T: +91 2266474444 E: [email protected] CIN: L24239MH 1949PLC007837